- Home
- PHAR vs PRO Comparison
PHAR vs PRO Comparison
Compare PHAR & PRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHAR | PRO |
|---|---|---|
| Founded | 1988 | 1985 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | PHAR | PRO |
|---|---|---|
| Price | $16.39 | $23.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $30.00 | $24.54 |
| AVG Volume (30 Days) | 21.0K | ★ 1.2M |
| Earning Date | 11-06-2025 | 10-27-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $362,274,000.00 | $351,682,000.00 |
| Revenue This Year | $24.80 | $10.50 |
| Revenue Next Year | $6.84 | $10.86 |
| P/E Ratio | $3,084.39 | ★ N/A |
| Revenue Growth | ★ 26.78 | 8.92 |
| 52 Week Low | $7.50 | $13.61 |
| 52 Week High | $18.12 | $29.84 |
Technical Indicators
Market Signals| Indicator | PHAR | PRO |
|---|---|---|
| Relative Strength Index (RSI) | 49.79 | 76.65 |
| Support Level | $15.76 | $23.06 |
| Resistance Level | $18.12 | $23.20 |
| Average True Range (ATR) | 0.83 | 0.05 |
| MACD | -0.12 | -0.04 |
| Stochastic Oscillator | 28.81 | 95.24 |
Price Performance
Historical ComparisonAbout PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About PRO PROS Holdings Inc.
Pros Holdings Inc provides software solutions that optimize shopping and selling experiences for both business-to-business and business-to-consumer companies across industry verticals in more than nearly 80 countries. Its PROS Platform is designed to help businesses create, optimize and market available offers and handle orders through both first- and third-party digital channels. The firm generates key revenue form the United States of America, Germany, The rest of Europe, Africa, Asia-Pacific, and Middle East regions.